Sign in
Taking people in United StatesPhase 2

KALM-B: Ketamine-assisted Psychotherapy (KAP) to Lessen Morbidity After Burn Injury

Key facts

Who runs it
Irma Fleming
Where
Salt Lake City, United StatesSee the site
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
12 people, planned
Started
24 Aug 2026
Expected to end
1 Apr 2028
Type of study
Interventional
Treatments tested
  • Preparatory Session
  • Ketamine-assisted Psychotherapy Session #1
  • Ketamine-assisted Psychotherapy Session #2
  • Integration Session
Record updated
27 August 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 29 criteriaShow less

Who can take part

  • Subjects 18 - 65 yrs with > 15 % Total Body Surface Area Burns
  • National Stressful Events Survey Acute Stress Disorder Short Scale (NSESSS) average total score>= 2 (severity scale of none (0), mild (1), moderate (2), severe (3), or extreme (4) ) prior to discharge from UUH

Who cannot take part

  • Allergy or previous adverse reactions to ketamine
  • Pending surgical interventions
  • Physical limitations from burn injury that preclude safe travel to outpatient visits or positioning for therapy
  • Current or prior history of PTSD diagnosis
  • Receiving ketamine treatments for psychiatric condition within the past 6 months
  • Subjects taking prohibited medications. A washout period of prohibited medications for a period of at least five half-lives should occur prior to study registration. These medications include antipsychotic medications, doses of benzodiazepines in excess of 20mg diazepam equivalents per day
  • Active systemic infection, sepsis, or hemodynamic instability
  • Personal history or first- or second-degree relatives with schizophrenia, bipolar affective disorder, delusional disorder, schizoaffective disorder, psychosis, or other psychotic spectrum illness
  • Currently meeting DSM-5 criteria for Dissociative Disorder, or other psychiatric conditions judged to be incompatible with the establishment of rapport or safe exposure to ketamine
  • Currently meeting DSM-5 criteria for Cluster B Personality Disorder
  • Current or history within the last two years of meeting DSM-V criteria of substance use disorder (excluding caffeine and nicotine)
  • Current substance use disorders may be identified through the drug urine screening test or undergoing treatment (methadone/Suboxone)
  • Congestive heart failure, including all New York Heart Association Classes
  • Angina pectoris, cardiac hypertrophy, cardiac ischemia, myocardial infarction
  • Uncontrolled hypertension at the time of enrollment (BP>140 systolic or 90 diastolic), coronary artery disease, artificial heart valve
  • History of hypersensitivity to ketamine
  • Seizure disorder
  • Moderate to severe dementia
  • History of significant traumatic brain injury
  • Any other condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures (e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, [patients may not receive the drug through a feeding tube], social/ psychological issues, etc.)
  • Prolonged or congenital long QT syndrome (>450 ms), serious cardiac arrhythmias, tachycardia, a clinically significant screening ECG abnormality
  • Lack of reliable transportation, caregiver support, or housing stability
  • Language barrier
  • Severe depression requiring immediate standard-of-care treatment (e.g., hospitalization)
  • Suicidal ideation over the past month as assessed as a yes to question 3, 4, or 5 on the Columbia-Suicide Severity Rating Scale, Suicidal Ideation section
  • Requires the use of supplemental oxygen
  • Require Propranolol for Burn Hypermetabolism

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

This trial is currently available in United States.

  • University Of Utah HealthSalt Lake City, United StatesContact: Claire Ausbeck, BATaking people

About the trial

What the trial wants to find out

A study looking at the safety and tolerability of KAP (Ketamine-Assisted Psychotherapy) in the burn population.

The group in the trial

  • Ketamine-Assisted PsychotherapyTreatment being tested

    All 12 study participants will be assigned to receive KAP treatment.

    Treatment: Preparatory Session, Ketamine-assisted Psychotherapy Session #1, Ketamine-assisted Psychotherapy Session #2, and Integration Session

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT07563296, who can take part
Record updated
27 August 2026